Anti-thrombotic and Anticoagulant Treatment in Interventional Cardiology

Journal of the Medical Association of Thailand

Volumn 81, Issue 1, 1998, Pages 41-46

  Mahanonda, Nithi ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; HEPARIN; HIRUDIN; HIRULOG; TICLOPIDINE;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG INDICATION; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 2442676785     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Wilentz JR, Sanborn TA, Haudenschild CC, et al. Platelet accumulation experimental angioplasty: time course in relation to vascular injury. Circulation 1987; 75: 636-42.
2. Ip J, Fuster V, Israel D, et al. The role of platelets, thrombin, and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991: 77B-88B.
3. Ring ME, Vicchione JJ, Fiore LD, et al. Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Cardiol 1991; 67: 1330-4.
4. Chesebro JH, Clements IP, Fuster V, et al. A platelet inhibitor drug trial in coronary artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein graft patency. N Engl J Med 1982; 307: 73-8.
5. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass opertation. N Engl J Med 1984; 310: 209-14.
6. Patrano C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-95.
7. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis affer percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
8. Theroux P, Lidon RM. Anticoagulants and their use in acute ischemic syndromes. In: Topol EJ, ed. Philadelphia: Textbook of interventional cardiology. WB Saunders, 1994.
9. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
10. Lacoste L, Lam JYT, Letchacovski G. Comparative antithrombotic efficacy of aspirin: 80mg vs 325mg daily. Circulation 1994; 90: I-552.
11. Dabaghi SF, Damat S, Hendricks O, et al. Low dose aspirin inhibits in vitro platelet aggregation within minutes after ingestion. Circulation 1992; 86: I-261.
12. Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. The effect of antiplatelet therapy on restenosis after experimental angioplasty, Am J Cardiol 1984; 53: 72C-76C.
13. Lam JVT, Chesebro JH, Steel PM, et al. Antithrombotic therapy for deep arterial injury by angioplasty. Circulation 1991; 84: 814-20.
14. Lacoste L, Lam JYT. Enhanced platelet thrombus formation in unstable angina. Circulation 1994: 90: 1374.
15. Noble S, Goa KL. Ticlopidine, a review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischemia and stroke. Drugs Aging 1996; 8: 214-32.
16. Raps EC, Galetta SL. Stroke prevention therapies and management of patient subgroups. Neurology 1995; 45: S19-24.
17. Schror K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.
18. Jeong M, Owen W, Staabon, et al. Does ticlopidine effect platelet deposit and acute stent thrombosis? Circulation 1995; 92: I-489.
19. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine alternates post-angioplasty thrombin generation. Circulation 1995; 92: I-608.
20. EPIC Investigators. Use of a monoclonal antibody directed against the platelet giycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
21. Topol EJ, Califf RM, Weisman HF, et al. On behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrelin for reduction of clinical resienosis: Results at six months. Lancet 1994; 343: 881-6.
22. Lefkovits J, Ivanhoe R, Anderson K, et al. Platelet IIb/IIIa receptor inhibition during PTCA for acute myocardial infarction: Insights from the EPIC trial. Circulation 1994; 90: I-564.
23. Linoff AM, Califf R, Anderson K, et al. Striking clinical benefit with platelet IIb/IIIa inhibition by C7E3 among patients with unstable angina: Outcome in the EPIC trial. Circulation 1994; 90: I-21.
24. Molitemo D, Califf R, Anderson K, et al. Activated clotting time is increased during coronary interventions with platelet IIb/IIIa antagonism: results from the EPIC trial. J Am Coll Cardiol 1994: 106A.
25. Kleinman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
26. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35-40.
27. Tcheng JE, Lincoff AM, Sigmon K. Platelet glycoprotein IIb/IIIa inhibition with integrelin during PTCA: The Impact trial. Circulation 1995; 92: I-543.
28. Serruys P, Herrman J, Simon R, et al. A comparison of Hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63.
29. Bittl JA, Strony J, Brinker JA, et al. Treatment with Bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina. N Engl J Med 1995; 333: 764-9.
30. Nakagawa Y, Iwasaki Y, Takeshi, Nobuyoshi M. Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78: 980-4.
31. Ferguson J, Dougherty K, Gaos C, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 1061-5.
32. Ahmed W, Meckel C, Grines C, et al. Relation between ischemic complications and activated clotting times during coronary angioplasty: Different profiles for heparin and Hirulog. Circulation 1995; 92: I-608.
33. Nairns CR, Hillegass WG, Nelson CL, et al. Activated clotting time predicts abrupt closure risk during angioplasty. J Am Coll Cardiol 1994; 23: 470A.
34. Blumenthal R, Wolff M, Resar J, et al. Preprocedural anticoagulation does not reduce angioplasty heparin requirements. Am Heart J 1993; 125: 1221.
35. Granger C, Armstrong P. For the GUSTO Iia investigators. Reinfarction following discontinuation of intravenous heparin or hirudin for unstable angina and acute myocardial infarction. Circulation 1995: 92: I-460.
36. Granger C, Miller J, Bovill E, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-35.
37. Flather M, Weitz J, Campeau J, et al. Evidence for rebound activation of the coagulation system after cessation of intravenous anticoagulant therapy for acute MI. Circulation 1995; 92: I-485.
38. Strony J, Ahmed W, Meckel C. et al. Clinical evidence for thrombin rebound after stopping heparin but not hirulog. Circulation 1995; 92: I-609.
39. Khan M, Sepulveda J, Jeroudi M, et al. Rebound increase in thrombin activity with associated decrease in antithrombin III levels after PTCA. Circulation 1995; 92: I-785.